Answers are grounded in this paper and cite their sources.
Clinical investigation evaluates antibody-oligonucleotide conjugate effects on myotonic dystrophy, indicating potential benefits.
Our results are consistent with delivery of del-desiran to muscle and amelioration of aberrant alternative splicing in some patients with myotonic dystrophy type 1; two serious adverse events occurred. These data support further clinical investigation. (Funded by Avidity Biosciences; ClinicalTrials.gov number, NCT05027269.).
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: